Fidler Miranda M, Reulen Raoul C, Bright Chloe J, Henson Katherine E, Kelly Julie S, Jenney Meriel, Ng Antony, Whelan Jeremy, Winter David L, Frobisher Clare, Hawkins Michael M
Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.
Thorax. 2018 Oct;73(10):959-968. doi: 10.1136/thoraxjnl-2017-210683. Epub 2018 May 10.
Exposure to radiation and/or chemotherapy during cancer treatment can compromise respiratory function. We investigated the risk of long-term respiratory mortality among 5-year cancer survivors diagnosed before age 40 years using the British Childhood Cancer Survivor Study (BCCSS) and Teenage and Young Adult Cancer Survivor Study (TYACSS).
The BCCSS comprises 34 489 cancer survivors diagnosed before 15 years from 1940 to 2006 in Great Britain. The TYACSS includes 200 945 cancer survivors diagnosed between 15 years and 39 years from 1971 to 2006 in England and Wales. Standardised mortality ratios and absolute excess risks were used.
Overall, 164 and 1079 respiratory deaths were observed in the BCCSS and TYACSS cohorts respectively, which was 6.8 (95% CI 5.8 to 7.9) and 1.7 (95% CI 1.6 to 1.8) times that expected, but the risks varied substantially by type of respiratory death. Greatest excess numbers of deaths were experienced after central nervous system (CNS) tumours in the BCCSS and after lung cancer, leukaemia, head and neck cancer and CNS tumours in the TYACSS. The excess number of respiratory deaths increased with increasing attained age, with seven (95% CI 2.4 to 11.3) excess deaths observed among those aged 50+ years in the BCCSS and three (95% CI 1.4 to 4.2) excess deaths observed among those aged 60+ years in the TYACSS. It was reassuring to see a decline in the excess number of respiratory deaths among those diagnosed more recently in both cohorts.
Prior to this study, there was almost nothing known about the risks of respiratory death after cancer diagnosed in young adulthood, and this study addresses this gap. These new findings will be useful for both survivors and those involved in their clinical management and follow-up.
癌症治疗期间暴露于辐射和/或化疗可能损害呼吸功能。我们利用英国儿童癌症幸存者研究(BCCSS)和青少年及青年成人癌症幸存者研究(TYACSS),调查了40岁前确诊的5年癌症幸存者的长期呼吸死亡风险。
BCCSS包括1940年至2006年在英国15岁前确诊的34489名癌症幸存者。TYACSS包括1971年至2006年在英格兰和威尔士15岁至39岁之间确诊的200945名癌症幸存者。使用标准化死亡率和绝对超额风险。
总体而言,BCCSS和TYACSS队列中分别观察到164例和1079例呼吸死亡,分别是预期死亡数的6.8倍(95%可信区间5.8至7.9)和1.7倍(95%可信区间1.6至1.8),但呼吸死亡类型的风险差异很大。BCCSS中中枢神经系统(CNS)肿瘤后死亡人数超额超额最多最多,TYACSS中肺癌、白血病、头颈癌和CNS肿瘤后死亡人数最多。呼吸死亡超额数随达到的年龄增加而增加,BCCSS中50岁以上人群中观察到7例(95%可信区间2.4至11.3)超额死亡,TYACSS中60岁以上人群中观察到3例(95%可信区间1.4至4.2)超额死亡。令人欣慰的是,在两个队列中,最近确诊的人群中呼吸死亡超额数有所下降。
在本研究之前,对于青年期确诊癌症后呼吸死亡风险几乎一无所知,本研究填补了这一空白。这些新发现对幸存者以及参与其临床管理和随访的人员都将有用。